Zhican Qu
Chief Executive Officer & Founder Nanolattix
Seminars
Wednesday 5th November 2025
Showcasing Early Clinical Profile of T320 ADC Targeting TF Across Solid Tumors & Development of Novels ADC to Combat Drug Resistance
2:00 pm
- Introducing IND-enabling preclinical profile of T320 ADC targeting TF in solid tumors
- Laying out ongoing clinical trial progress of T320 ADC
- Exploring future translational approach of bispecific and dual payload ADCs with design innovation to reduce drug resistance
